According to a recent report from Medtech Insight, general and pelvic endoscopic/laparoscopic surgeries such as gastric bypass, endometrial ablation, laparoscopically-assisted vaginal hysterectomy (LAVH), appendectomy and prostatectomy were performed more than 2.8 million times in 2008. This translates to the U.S. market for products used in general and pelvic endoscopic surgery to be valued at more than $3.3 billion. Over the next five years, this market is expected to grow at a 9 percent compounded annual rate, bringing it to $5.2 billion by 2013.
The report states that despite the current economic recession, strong pricing pressures and competition, this market is expected to exhibit healthier-than-average growth due to demographics, ongoing demand for less invasive, less-costly surgery, increased surgeon training and the adaption of new technologies, including robotic surgical systems and next-generation instrumentation.
In addition, emerging scarless techniques, including reducing the surgical access to a single incision or via natural orifices such as the umbilicus, have resulted in the development of several novel surgical instruments and systems that may significantly impact the field of laparoscopy.